Critical issues in peripheral arterial disease detection and management: A call to action

Archives of Internal Medicine

Volumn 163, Issue 8, 2003, Pages 884-892

  Belch, Jill J F ^a   Topol, Eric J ^b   Agnelli, Giancarlo ^c   Bertrand, Michel ^d   Califf, Robert M ^e   Clement, Denis L ^f   Creager, Mark A ^g   Easton, J Donald ^h   Gavin III, James R ⁱ   Greenland, Philip ^j   Hankey, Graeme ^k   Hanrath, Peter ^l   Hirsch, Alan T ^m   Meyer, Jürgen ⁿ   Smith, Sidney C ^o   Sullivan, Frank ^p   Weber, Michael A ^q  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f GHENT UNIVERSITY   (Belgium)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁿ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^o Division of Cardiology   (United States)

^p Tayside Centre for General Practice   (United Kingdom)

^q SUNY Downstate Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANKLE BRACHIAL INDEX; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC TEST; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEG BLOOD FLOW; LIMB ISCHEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRESSURE MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SMOKING CESSATION; SYMPTOMATOLOGY; VASCULAR DISEASE; ARTERIOSCLEROSIS; COMORBIDITY; MASS SCREENING; METHODOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

ARTERIAL OCCLUSIVE DISEASES; ARTERIOSCLEROSIS; CLINICAL TRIALS; COMORBIDITY; HUMANS; MASS SCREENING; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0037471546     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.8.884     Document Type: Review

References (64)

1. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94:3026-3049.
2. Hirsch AT, Halverson SL, Treat-Jacobson D, et al. The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med. 2001; 6:87-96.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
4. Elhadd TA, Robb R, Jung RT, Stonebridge PA, Belch JJF. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Practical Diabetes Int. 1999;16:163-166.
5. Newman AB, Shemanski L, Manolio TA, et al, for the Cardiovascular Health Study Collaborative Research Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
6. Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2000;86:615-618.
7. Sikkink CJ, van Asten WN, van't Hof MA, van Langen H, van der Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med. 1997;2:169-173.
8. Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 1997;131:115-125.
9. West JA. Cost-effective strategies for the management of vascular disease. Vasc Med. 1997;2: 25-29.
10. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
12. Zusman RM, Chesebro JH, Comerota A, et al. An tiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection. Clin Cardiol. 1999;22:559-573.
13. Priollet P. Quality of life and peripheral arterial disease: perspectives for the future. Drugs. 1998;56 (suppl 3):49-58.
14. Regensteiner JG, Treat-Jacobson D, Walsh ME, et al. PARTNERS: the impact of peripheral arterial disease (PAD) on health-related quality of life (HQL) [abstract]. Circulation. 2000;102(suppl 2): 11-400.
15. Treat-Jacobson DT, Halverson SL, Ratchford A, Regensteiner JG, Lindquist R, Hirsch AT. A patient-derived perspective of health-related quality of life with peripheral arterial disease. J Nurs Scholarsh. 2002;34:55-60.
16. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18:185-192.
17. Hooi JD, Stoffers HE, Kester AD, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease: the Limburg Peripheral Arterial Occlusive Disease (PAOD) Study. Scand J Prim Health Care. 1998;16:177-182.
18. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241-245.
19. McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the Women's Health and Aging Study. Circulation. 2000;101:1007-1012.
20. Simons PC, Algra A, Eikelboom BC, Grobbee DE, van der Graaf Y, for the SMART Study Group. Carotid artery stenosis in patients with peripheral arterial disease: the SMART study. J Vasc Surg. 1999;30:519-525.
21. House AK, Bell R, House J, Mastaglia F, Kumar A, D'Antuono M. Asymptomatic carotid artery stenosis associated with peripheral vascular disease: a prospective study. Cardiovasc Surg. 1999; 7:44-49.
22. Dormandy JA. Epidemiology and natural history of arterial diseases of the lower limbs. Rev Prat. 1995;45:32-36.
23. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
24. Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of peripheral arterial disease (PAD). J Vasc Surg. 2000;31:S1-S296.
25. Dormandy JA, Rutherford RB, for the TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of peripheral arterial disease (PAD). Int Angiol. 2000;19(suppl 1):1-310.
26. Leng GC, Lee AJ, Fowkes FGR, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172-1181.
27. American Cancer Society. Cancer Facts & Figures 2000. Available at: http://www.cancer.org/docroot /stt/content/stt_1x_2000_facts_and_figures.asp. Accessed 2000.
28. Kempczinski RF, Bernhard VM. Introduction and general considerations [section VIII, management of chronic lower limb ischaemia]. In: Rutherford RB, ed. Vascular Surgery. 3rd ed. Philadelphia, Pa: WB Saunders; 1989:643-652.
29. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96:44-49.
30. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-515.
31. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133-138.
32. Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993;125:863-872.
33. Criqui MH, Fronek A, Klauber MR, Barrett Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985;71:516-521.
34. Leng GC, Fowkes FGR. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101-1109.
35. Dormandy J, Heeck L, Vig S. Intermittent claudication: a condition with underrated risks. Semin Vasc Surg. 1999;12:96-108.
36. Fowkes FGR, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384-392.
37. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
38. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334: 155-159.
39. Ferrini R, Mannino E, Ramsdell E, Hill L. Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. Am J Prev Med. 1996;12:340-341.
40. Society for Vascular Medicine and Biology (SVMB) and Society for Vascular Nursing (SVM). Peripheral Arterial Disease: Marker of Cardiovascular Risk. Manchester, Mass: SVMB/SVM; 1999.
41. Ramsay LE, Williams B, Johnston GD, et al, for the British Hypertension Society. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999;13:569-592.
42. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ. 2000;320: 705-708.
43. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease: secondary prevention of peripheral vascular disease. BMJ. 2000;320:1262-1265.
44. Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;93(suppl 1A):8S-12S.
45. American Lung Association. Trends in Tobacco Use. New York, NY: American Lung Association, Epidemiology and Statistics Unit; 2001.
46. Gotto AM Jr. Statin therapy: where are we? where do we go next? Am J Cardiol. 2001;87(suppl): 13B-18B.
47. Aronow WS. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2001; 56A:M138-M145.
48. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1308.
49. SIGN (Scottish Intercollegiate Guidelines Network). Lipids and the Primary Prevention of Coronary Heart Disease: A National Clinical Guideline. Edinburgh, Scotland: SIGN; 1999. Publication 40.
50. Cruickshank JM. The case for beta-blockers as first-line antihypertensive therapy. J Hypertens Suppl. 1992;10:S21-S27.
51. Systolic Hypertension in the Elderly Program Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
52. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
53. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
54. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-713.
55. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
56. Beebe HG. Intermittent claudication: effective medical management of a common circulatory problem. Am J Cardiol 2001;87:14D-18D.
57. Tjon JA, Riemann LE. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Syst Pharm. 2001;58:485-496.
58. Santilli JD, Santilli SM. Chronic critical limb ischemia: diagnosis, treatment and prognosis. Am Fam Physician. 1999;59:1899-1908.
59. SIGN (Scottish Intercollegiate Guidelines Network). Antithrombotic Therapy: A National Clinical Guideline. Edinburgh, Scotland: SIGN; 1999. Publication 36.
60. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 2001;119(suppl):283S-299S.
61. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke. 1999;30:2502-2511.
62. SIGN (Scottish Intercollegiate Guidelines Network). Drug Therapy for Peripheral Vascular Disease: A National Clinical Guideline, Edinburgh, Scotland: SIGN; 1998. Publication 27.
63. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA. 1995;274:975-980.
64. Current Procedural Terminology (CPT). Chicago, Ill: American Medical Association; 2001.